Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2012-09-01
It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75%
hypertonic glucose of sclerotherapy in lower limbs´ reticular veins. It will be included only
adult women with reticular veins on the side of the thighs and mild venous insufficiency
(CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.
Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins
Completed
UPECLIN HC FM Botucatu Unesp
Phase 4
2012-09-01
It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75%
hypertonic glucose of sclerotherapy in lower limbs´ reticular veins. It will be included only
adult women with reticular veins on the side of the thighs and mild venous insufficiency
(CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
Completed
Boston Scientific Corporation
Phase 4
2015-05-01
The purpose of this study is to evaluate pain the patient experienced following treatment of
varicose veins with Varithena® compared to radiofrequency ablation.
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
Completed
BTG International Inc.
Phase 4
2015-05-01
The purpose of this study is to evaluate pain the patient experienced following treatment of
varicose veins with Varithena® compared to radiofrequency ablation.
Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2015-01-01
It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75%
hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only
adult women with reticular veins on the side of the thighs and mild venous insufficiency
(CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
